The Effectivity and Safety of Naltrexone/Bupropion in Patients Suffering from Overweight and Obesity in a Real-World Setting.

IF 4.7 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Obesity Facts Pub Date : 2025-04-21 DOI:10.1159/000545967
Marijn T F Jense, Lars Knibbeler, Roel P L M Hoogma, Inge H Palm-Meinders, Jan Willem M Greve, Evert-Jan G Boerma
{"title":"The Effectivity and Safety of Naltrexone/Bupropion in Patients Suffering from Overweight and Obesity in a Real-World Setting.","authors":"Marijn T F Jense, Lars Knibbeler, Roel P L M Hoogma, Inge H Palm-Meinders, Jan Willem M Greve, Evert-Jan G Boerma","doi":"10.1159/000545967","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Bariatric and metabolic surgery carries risks of complications and may affect food tolerance. For patients who are overweight or do not meet surgical criteria, alternative weight loss strategies must be explored. One such option is naltrexone/bupropion (NB) treatment. This study evaluates the impact of NB treatment combined with lifestyle intervention on weight loss over 12 months in a real-world setting.</p><p><strong>Methods: </strong>A retrospective cohort study included all patients initiating NB treatment at the Dutch Obesity Clinic from February 2021 to October 2022.</p><p><strong>Results: </strong>Among 98 patients (17.5% male; median age 49 [43-53]; median BMI 35.4 [33.0-39.1]), mean percentage total weight loss (SD) was 7.9% (4.2) at 3 months, 10.3% (6.5) at 6 months, and 11.5% (8.3) at 12 months. During the buildup phase, 23.5% of patients experienced nausea/vomiting, 19.4% reported headaches, and 28.6% had constipation. At optimal dosage, 39.8% experienced side effects, with 33% reporting multiple symptoms. Treatment discontinuation within 12 months occurred in 52.7% of patients.</p><p><strong>Conclusion: </strong>NB treatment combined with lifestyle intervention results in significant weight loss after 6 and 12 months. Despite high discontinuation rates due to multiple reasons including side effects, NB treatment in combination with lifestyle intervention may be of interest for a specific population.</p>","PeriodicalId":19414,"journal":{"name":"Obesity Facts","volume":" ","pages":"1-8"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148336/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Facts","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545967","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Bariatric and metabolic surgery carries risks of complications and may affect food tolerance. For patients who are overweight or do not meet surgical criteria, alternative weight loss strategies must be explored. One such option is naltrexone/bupropion (NB) treatment. This study evaluates the impact of NB treatment combined with lifestyle intervention on weight loss over 12 months in a real-world setting.

Methods: A retrospective cohort study included all patients initiating NB treatment at the Dutch Obesity Clinic from February 2021 to October 2022.

Results: Among 98 patients (17.5% male; median age 49 [43-53]; median BMI 35.4 [33.0-39.1]), mean percentage total weight loss (SD) was 7.9% (4.2) at 3 months, 10.3% (6.5) at 6 months, and 11.5% (8.3) at 12 months. During the buildup phase, 23.5% of patients experienced nausea/vomiting, 19.4% reported headaches, and 28.6% had constipation. At optimal dosage, 39.8% experienced side effects, with 33% reporting multiple symptoms. Treatment discontinuation within 12 months occurred in 52.7% of patients.

Conclusion: NB treatment combined with lifestyle intervention results in significant weight loss after 6 and 12 months. Despite high discontinuation rates due to multiple reasons including side effects, NB treatment in combination with lifestyle intervention may be of interest for a specific population.

纳曲酮/安非他酮治疗超重和肥胖患者的有效性和安全性
目的减肥和代谢手术有并发症的风险,并可能影响食物耐受性。对于超重或不符合手术标准的患者,必须探索其他减肥策略。其中一个选择是纳曲酮/安非他酮(NB)治疗。本研究在现实世界中评估了NB治疗结合生活方式干预对12个月体重减轻的影响。方法回顾性队列研究纳入了2021年2月至2022年10月在荷兰肥胖诊所接受NB治疗的所有患者。结果98例患者中男性占17.5%;中位年龄49岁[43-53];中位BMI为35.4[33.0-39.1]),3个月时的平均总体重减轻百分比(SD)为7.9%(4.2),6个月时为10.3%(6.5),12个月时为11.5%(8.3)。在积聚阶段,23.5%的患者出现恶心/呕吐,19.4%的患者出现头痛,28.6%的患者出现便秘。在最佳剂量下,39.8%出现副作用,33%报告多重症状。52.7%的患者在12个月内停药。结论NB治疗联合生活方式干预后6个月和12个月体重明显减轻。尽管由于包括副作用在内的多种原因导致的高停药率,但NB治疗与生活方式干预相结合可能对特定人群感兴趣。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Obesity Facts
Obesity Facts 医学-内分泌学与代谢
CiteScore
6.80
自引率
5.60%
发文量
77
审稿时长
6-12 weeks
期刊介绍: ''Obesity Facts'' publishes articles covering all aspects of obesity, in particular epidemiology, etiology and pathogenesis, treatment, and the prevention of adiposity. As obesity is related to many disease processes, the journal is also dedicated to all topics pertaining to comorbidity and covers psychological and sociocultural aspects as well as influences of nutrition and exercise on body weight. The editors carefully select papers to present only the most recent findings in clinical practice and research. All professionals concerned with obesity issues will find this journal a most valuable update to keep them abreast of the latest scientific developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信